2026
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
29 February 2024
dsm-firmenich, innovators in nutrition, health, and beauty, today announces the publication of its first Integrated Annual Report (IAR).
2 May 2023
Prioritising profitability over sales volumes has supported our margins, which improved sequentially into the first quarter.”
28 April 2023
Following the Offering Circular published on 22 November 2022, DSM and DSM-Firmenich are required to announce transactions in relation to the ordinary shares in their respective share capital in accordance with the Dutch public offer rules.
26 April 2023
Following the Offering Circular published on 22 November 2022, DSM and DSM-Firmenich are required to announce transactions in relation to the ordinary shares in their respective share capital in accordance with the Dutch public offer rules.
25 April 2023
Following the Offering Circular published on 22 November 2022, DSM and DSM-Firmenich are required to announce transactions in relation to the ordinary shares in their respective share capital in accordance with the Dutch public offer rules.
24 April 2023
Following the Offering Circular published on 22 November 2022, DSM and DSM-Firmenich are required to announce transactions in relation to the ordinary shares in their respective share capital in accordance with the Dutch public offer rules.
21 April 2023
Following the Offering Circular published on 22 November 2022, DSM and DSM-Firmenich are required to announce transactions in relation to the ordinary shares in their respective share capital in accordance with the Dutch public offer rules.
20 April 2023
Following the Offering Circular published on 22 November 2022, DSM and DSM-Firmenich are required to announce transactions in relation to the ordinary shares in their respective share capital in accordance with the Dutch public offer rules.
19 April 2023
Following the Offering Circular published on 22 November 2022, DSM and DSM-Firmenich are required to announce transactions in relation to the ordinary shares in their respective share capital in accordance with the Dutch public offer rules.
19 April 2023
DSM announces that it has entered into exclusive negotiations with Adare Pharma Solutions in order to acquire Adare Biome, a pioneer in the development and manufacturing of postbiotics, for an enterprise value of €275 million. This transaction represents an estimated 2023 EV/EBITDA multiple of 18x.
6 April 2023
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
5 April 2023
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
4 April 2023
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
3 April 2023
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
3 April 2023
Royal DSM announces the completion of the sale of its Engineering Materials business to Advent International and LANXESS for an Enterprise Value of €3.85 billion.
31 March 2023
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
30 March 2023
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
30 March 2023
Dutch dairy company Royal FrieslandCampina, DSM, and feed supplier Agrifirm have successfully incorporated Bovaer® into the regular farming activities of 158 dairy farms in the Netherlands in the world’s first large-scale on-farm use of the methane-reducing feed additive for cattle.
29 March 2023
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
29 March 2023
DSM reveals the first audited results of its progress in helping to address urgent societal and environmental challenges linked to how the world produces and consumes food.
28 March 2023
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
27 March 2023
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
24 March 2023
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
23 March 2023
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
22 March 2023
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
21 March 2023
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
20 March 2023
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
17 March 2023
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
16 March 2023
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
15 March 2023
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
14 March 2023
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
13 March 2023
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
8 March 2023
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
7 March 2023
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
6 March 2023
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
3 March 2023
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
2 March 2023
Royal DSM, a global purpose-led, performance-driven leader in Health, Nutrition & Bioscience, today announces the publication of its 2022 Integrated Annual Report (IAR).
27 February 2023
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
24 February 2023
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
20 February 2023
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
17 February 2023
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
16 February 2023
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
16 February 2023
DSM delivered a solid performance in 2022 against a background of continued global supply chain challenges and significantly higher energy and raw materials costs, consolidating the strong growth of 2021. Pricing actions to counter higher costs, supported top-line growth, however with a price-cost gap impacting near-term margins, especially in Animal, Nutrition & Health.
13 February 2023
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
10 February 2023
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
8 February 2023
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
3 February 2023
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
2 February 2023
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
1 February 2023
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
30 January 2023
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
24 January 2023
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
23 January 2023
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
23 January 2023
DSM today held an Extraordinary General Meeting of Shareholders (EGM). The DSM Shareholders approved the proposed merger between DSM and Firmenich International SA (Firmenich) and voted in favour of all related resolutions as set out in the notice of the EGM.
20 January 2023
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
19 January 2023
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
18 January 2023
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
17 January 2023
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
16 January 2023
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
13 January 2023
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
12 January 2023
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
11 January 2023
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
10 January 2023
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
9 January 2023
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
6 January 2023
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
5 January 2023
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
4 January 2023
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
3 January 2023
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
2 January 2023
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
30 December 2022
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
29 December 2022
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
27 December 2022
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
23 December 2022
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
20 December 2022
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
19 December 2022
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
15 December 2022
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.
13 December 2022
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules.
6 December 2022
Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules.
30 November 2022
The plant will significantly increase global production of Bovaer®, DSM’s unique methane-reducing feed additive for cattle. In an official groundbreaking ceremony attended by the First Minister of Scotland, Nicola Sturgeon, and Dimitri de Vreeze, Co-CEO of DSM, the company marked the next step in its plan to use Bovaer® to reduce global methane emissions and contribute to worldwide methane reduction targets.
17 November 2022
DSM confirms that its target to cut scope 1 and 2 greenhouse gas (GHG) emissions has been determined to be in line with the latest climate science and in keeping global warming to no more than 1.5°C by the Science Based Targets initiative (SBTi).
1 November 2022
DSM’s trading update for the first nine months of 2022 is out now and our Health, Nutrition & Bioscience businesses all delivered good sales growth. Market demand remained resilient in what is a challenging macro-economic environment with the rising cost inflation.
1 September 2022
DSM today announces the completion of its acquisition of Prodap, a leading animal nutrition and technology company in Brazil.
1 September 2022
DSM, a global purpose-led science-based company, today announces the completion of the sale of its Protective Materials business to Avient Corporation
2 August 2022
A good half year performance underpinned by resilient market demand.
2 August 2022
DSM announces that it pledges to purchase all of its electricity worldwide from renewable sources
28 June 2022
Royal DSM, a global purpose-led science-based company, today provides the investment community with comparative quarterly figures for 2021 and 2022 Q1.
7 June 2022
Royal DSM, a global purpose-led science-based company, announces it has reached an agreement to acquire Prodap, a Brazilian animal nutrition and technology company that combines technology offerings, consulting services, and customized nutritional solutions to drive efficiency and sustainability in animal farming.
31 May 2022
Royal DSM, a global purpose-led science-based company, today announces that it has reached an agreement to sell its Engineering Materials business to Advent International and LANXESS for an Enterprise Value of €3.85 billion.
24 May 2022
Royal DSM and the World Food Programme (WFP) have agreed to extend their partnership and scale up rice fortification worldwide for a further three years. The partnership will seek to improve the availability and accessibility of nutritious foods in order to reach vulnerable people where key dietary decisions are made.
10 May 2022
Royal DSM, a global purpose-led science-based company, confirmed its resolution to declare a dividend for the financial year 2021 of €2.50 per ordinary share was passed today, 10 May 2022, at its Annual General Meeting of Shareholders.
10 May 2022
Royal DSM, a global purpose-led science-based company, today held its Annual General Meeting of Shareholders. All the resolutions on the agenda were approved by the shareholders.
10 May 2022
Royal DSM, a global purpose-led science-based company, the United Nations’ children’s agency UNICEF, and Swiss-based nutrition think tank and incubator Sight and Life have renewed their long-term partnership to deliver better nutrition for at-risk groups in countries in Sub-Saharan Africa and Asia.
10 May 2022
Royal DSM, a global purpose-led science-based company, has repurchased 40,085 of its own shares in the period from 2 May 2022 up to and including 6 May 2022 at an average price of €156.08.
3 May 2022
Royal DSM, a global purpose-led science-based company, has repurchased 157,671 of its own shares in the period from 25 April 2022 up to and including 29 April 2022 at an average price of €156.34.
27 April 2022
Elanco Animal Health Incorporated (ELAN: NYSE) and Royal DSM have created a strategic alliance connecting two leading, sustainability-focused companies to address one of society’s most significant opportunities of the decade, mitigating climate change by reducing greenhouse gas emissions from farming. Elanco has secured the exclusive U.S. licensing rights to develop, manufacture and commercialize Bovaer® for beef and dairy cattle.
26 April 2022
Royal DSM, a global purpose-led science-based company, has repurchased 142,403 of its own shares in the period from 18 April 2022 up to and including 22 April 2022 at an average price of €155.73.
20 April 2022
European dairy cooperative Arla Foods and global purpose-led science-based company, Royal DSM, are set to start a large-scale on-farm pilot with the methane reducing feed additive Bovaer® on 10,000 dairy cows across three European countries.
20 April 2022
Royal DSM, a global purpose-led science-based company, has repurchased 101,258 of its own shares in the period from 11 April 2022 up to and including 15 April 2022 at an average price of €158.07.
20 April 2022
Royal DSM, a global purpose-led science-based company, today announces that it has reached an agreement to sell its Protective Materials business to Avient Corporation for an Enterprise Value of €1.44 billion.
12 April 2022
Royal DSM, a global purpose-led science-based company, has repurchased 173,491 of its own shares in the period from 4 April 2022 up to and including 8 April 2022 at an average price of €162.36.
5 April 2022
Royal DSM, a global purpose-led science-based company, has repurchased 171,521 of its own shares in the period from 28 March 2022 up to and including 1 April 2022 at an average price of €162.39.
4 April 2022
Royal DSM, a global purpose-led science-based company, today provides preliminary comparative financial figures for 2021 following the establishment of DSM’s Health, Nutrition & Bioscience (“HNB”) structure, which became effective as of 1 January 2022.
29 March 2022
Royal DSM, a global purpose-led science-based company, has repurchased 205,518 of its own shares in the period from 21 March 2022 up to and including 25 March 2022 at an average price of €160.28.
24 March 2022
The Bovaer® pilot collaboration between the Dutch companies FrieslandCampina, DSM, and Agrifirm marks an important step forward in increasing the sustainability of the dairy sector. Some 200 FrieslandCampina dairy farms in the Netherlands will take part in the pilot in the second half of 2022. Providing the results are positive, the use of Bovaer® will be further upscaled from 2023.
22 March 2022
Update March 22nd: DSM has repurchased 176,083 of its own shares in the period from 10 March 2022 up to and including 11 March 2022 at an average price of €150.87.
15 March 2022
DSM has repurchased 176,083 of its own shares in the period from 10 March 2022 up to and including 11 March 2022 at an average price of €150.87.
10 March 2022
Royal DSM, a global purpose-led science-based company, today announces the repurchase, starting 10 March 2022, of 1,330,000 ordinary shares.
2 March 2022
DSM publishes 2021 annual report on the company's social, environmental and financial performance for the year.
24 February 2022
Royal DSM, a global purpose-led science-based company, announces that European Union (EU) member states approved the marketing of the methane-reducing feed additive for dairy cows, Bovaer®, in the EU. After inclusion in the EU registry, expected in the coming weeks, it is the first time a feed additive authorised in the EU for environmental benefits can be marketed. This marks a significant milestone for DSM, paving the way for Bovaer® to revolutionize the dairy market.
15 February 2022
Strong financial growth alongside significant progress toward our sustainability and strategy ambitions made 2021 a year to be proud of.
17 December 2021
Royal DSM, a global purpose-led science-based company, today announces the completion of its acquisition of Vestkorn Milling for an enterprise value of €65m. This acquisition of one of Europe’s leading producers of pea- and bean-derived ingredients for plant-based protein products was first announced on 29 November 2021.
29 November 2021
Royal DSM, a global purpose-led science-based company, announces today that it has signed an agreement to acquire Norwegian company Vestkorn Milling, one of Europe’s leading producers of pea- and bean-derived ingredients for plant-based protein products, for an enterprise value of €65m.
19 November 2021
DSM has received a positive European Food Safety Authority (EFSA) opinion for the use of its novel methane-reducing feed additive for ruminants, Bovaer®, in the European Union. The EFSA opinion confirms that the feed additive reduces enteric methane emissions from dairy cows and is safe for the animal and the consumer.
9 November 2021
DSM is planning to realize large scale production capacity for its novel methane-reducing feed additive for ruminants, Bovaer® with a new plant at its existing site in Dalry, Scotland, supported by Scottish Enterprise.
2 November 2021
DSM delivers a very good nine months of the year.
19 October 2021
DSM acquires First Choice Ingredients, a leading supplier of dairy-based savory flavorings.
14 September 2021
Quantifiable commitments aim to address how the world produces and consumes food by 2030.
14 September 2021
DSM is simplifying its operating structure and reorganizing its Health, Nutrition & Bioscience activities into three Business Groups.
8 September 2021
The four plants will become among the first in the province to run on renewable energy.
3 September 2021
DSM to acquire developer of clean label, fermented dairy and dairy-based savory flavorings for taste and functional solutions.
31 August 2021
DSM has completed the repurchase 250,000 shares announced on 9 August 2021 for a total consideration of €44.6 million.
24 August 2021
DSM repurchased 109,792 shares from 16 to 20 August 2021 at an average price of €178.66.
17 August 2021
DSM repurchased 80,268 shares from 9 to 13 August 2021 at an average price of €175.75.
12 August 2021
New Power Purchase Agreement (PPA) will dramatically reduce DSM's CO2 emissions by approximately 50,000 tons/year.
9 August 2021
DSM will repurchase 250,000 ordinary shares to cover commitments for the interim stock dividend 2021.
3 August 2021
DSM accelerates its 30% greenhouse gas (GHG) emissions reduction target to 50% by 2030.
3 August 2021
DSM delivers very good first half year results, with full year outlook updated to reflect stronger Materials performance.
27 July 2021
DSM acquires biotech start-up Midori, developers of breakthrough eubiotics for more sustainable animal farming.
15 July 2021
New office to exemplify DSM’s culture and philosophy of hybrid working and be an inspiring environment for people to connect and collaborate.
13 July 2021
DSM informs its stakeholders that CVC Capital Partners today announced the proposed sale of AOC.
17 June 2021
DSM has completed the repurchase of 800,000 of its own shares at an average price of €150.36.
16 June 2021
€500 million 1.375% bond originally due to mature in September 2022 redeemed early.
15 June 2021
DSM repurchased 66,456 shares from 7 to 11 June 2021 at an average price of €152.02.
8 June 2021
DSM repurchased 117,895 shares from 31 May to 4 June 2021 at an average price of €151.73.
3 June 2021
Sale completes divestment of all DSM’s solar activities.
1 June 2021
DSM repurchased 102,721 shares from 24 to 28 May 2021 at an average price of €151.13.
25 May 2021
DSM repurchased 126,930 shares from 17 to 21 May 2021 at an average price of €148.27.
19 May 2021
€500 million 1.375% bond issued 24 September 2015 to be redeemed earlier than scheduled.
18 May 2021
DSM repurchased 145,703 shares from 10 to 14 May 2021 at an average price of €147.94.
18 May 2021
Get on your bike for the DSM Keep Challenging Series. Sign-up now!
11 May 2021
DSM repurchased 192,978 shares from 3 to 7 May 2021 at an average price of €151.32.
7 May 2021
Joint venture is first to deliver professional facemasks with filter material made entirely on Dutch soil.
6 May 2021
DSM declares a dividend for the 2020 financial year of €2.40 per ordinary share.
6 May 2021
DSM held a virtual Annual General Meeting of Shareholders on 6 May 2021 when shareholders approved all resolutions on the agenda.
6 May 2021
Summary of the resolutions and voting at DSM's most recent Annual General Meeting of Shareholders held virtually on 6 May 2021.
5 May 2021
DSM delivers very good Q1 with sales +7% and adjusted EBITDA +13%, updates Outlook 2021 reflecting strong Materials recovery.
29 April 2021
Cancellation concludes reduction in share capital following share buyback program executed from 1 April 2019 to February 2020.
1 April 2021
Sale to Covestro agreed in September 2020 for an equity value of €1.6 billion has finalized today.
31 March 2021
DSM acquires business consisting of 7 bio-based intermediate products to add to existing Aroma Ingredients portfolio.
16 March 2021
DSM will repurchase 800,000 ordinary shares to cover commitments for the final stock dividend 2020.
11 March 2021
DSM to sell residual solar backsheet business to Worthen Industries, Inc. following the sale of its solar coatings business to Covestro.
4 March 2021
Supervisory Board appoints Thomas Leysen to succeed Rob Routs as Chair and proposes Corien M. Wortmann-Kool as a new member.
2 March 2021
DSM publishes 2020 annual report on the company's social, environmental and financial performance for the year.
16 February 2021
DSM posts solid results in a challenging COVID-19 environment, continues to make good progress on execution of long-term strategic plan.
20 January 2021
Chris Goppelsroeder to retire on 1 April 2021 with DSM's Co-CEO Dimitri de Vreeze stepping into the role.
11 January 2021
The Artificial Intelligence Lab for Biosciences first of its kind in Europe to apply artificial intelligence to full-scale biomanufacturing,
6 January 2021
It is with sadness that we share with you the news of the passing away of our former Managing Board Chairman, Hans van Liemt.
4 December 2020
Strategic partnership with Team Sunweb sees professional cycling team transform into Team DSM for 2021 season onwards.
3 November 2020
DSM reports a solid first nine months in a challenging COVID-19 environment, with a continuing robust performance in Q3.
8 October 2020
DSM’s Resins & Functional Materials businesses moved to discontinued operations with their agreed sale to Covestro AG.
2 October 2020
DSM acquires Erber's Biomin specialty animal nutrition and health & Romer Labs food/feed safety diagnostics businesses.
30 September 2020
DSM to sell its Resins & Functional Materials and associated businesses to Covestro AG for an Equity Value of €1.6 billion.
24 September 2020
DSM's Supervisory Board nominates Mrs. Carla Mahieu for appointment as a new Supervisory Board member at next AGM.
4 September 2020
Partners investing several million €'s on manufacturing equipment and construction of new manufacturing facilities in Netherlands.
1 September 2020
DSM repurchased 27,328 shares from 24 to 28 August 2020 at an average price of €134.92.
25 August 2020
DSM repurchased 70,444 shares from 17 to 21 August 2020 at an average price of €131.13.
18 August 2020
DSM repurchased 102,228 shares from 7 to 14 August 2020 at an average price of €129.61.
7 August 2020
Repurchase of 200,000 ordinary shares equivalent to approximately €25 million on 6 August 2020.
4 August 2020
DSM reports a solid H1 2020 in a challenging COVID-19 environment, overall earnings outlook remains suspended.
13 July 2020
Cristina Monteiro appointed Executive Vice President People & Organization and member of the Executive Committee as of 1 September 2020.
1 July 2020
Zhou Tao (Joe) succeeds Dr. Weiming Jiang as President DSM China as of 1 July 2020.
17 June 2020
New bonds in two tranches of €500m allow DSM to lock-in low interest rates to finance the acquisition of the Erber Group.
12 June 2020
As prudent measure given Covid-19 environment and acquisition of Erber Group, DSM cancels remainder of €1 billion share buy-back program.
12 June 2020
DSM adds Erber Group’s mycotoxin risk and gut health performance management and food and feed safety diagnostic solutions to portfolio.
8 May 2020
DSM declares a dividend for the financial year 2019 of €2.40 per ordinary share.
8 May 2020
DSM held a virtual Annual General Meeting of Shareholders on 8 May 2020 when shareholders approved all resolutions on the agenda.
8 May 2020
Summary of the resolutions and voting at DSM's Annual General Meeting of Shareholders 2020.
7 May 2020
DSM will produce sufficient swabs to meet the entire country’s testing needs for the next three months.
7 May 2020
DSM reports a solid Q1 2020, suspends overall earnings outlook given current limited visibility in Materials.
28 April 2020
Consortium of AFPRO Filters, Auping and DSM has begun large-scale production of FFP2 facemasks for healthcare workers.
21 April 2020
DSM signs largest renewable energy Power Purchase Agreement (PPA) to date.
1 April 2020
DSM acquires world's leading supplier of Human Milk Oligosaccharides (HMO) for early life nutrition applications.
26 March 2020
We are humbled by our people’s efforts and want to provide a broader update on how DSM is responding to the constantly evolving situation.
24 March 2020
DSM repurchased 239,127 shares from 16 to 20 March 2020 at an average price of €89.77.
17 March 2020
DSM repurchased 705,494 shares from 9 to 13 March 2020 at an average price of €96.33.
10 March 2020
DSM repurchased 455,379 shares from 2 to 6 March 2020 at an average price of €106.13.
2 March 2020
DSM will repurchase 1,400,000 ordinary shares to cover share plans and stock dividend.
27 February 2020
2019 Integrated Annual Report on DSM's performance and progress during 2019 in terms of People, Planet and Profit published.
25 February 2020
Helen Mets appointed Executive Vice President Materials and member of the Executive Committee as of 1 March 2020.
25 February 2020
DSM repurchased 183,602 shares from 17 to 21 February 2020 at an average price of €115.01.
21 February 2020
DSM to acquire world's leading supplier of Human Milk Oligosaccharides (HMO) for early life nutrition applications.
18 February 2020
DSM repurchased 80,423 shares from 10 to 14 February 2020 at an average price of €116.31.
13 February 2020
DSM delivered a good financial performance for the year and achieved the key milestones in the first year of its Strategy 2021.
11 February 2020
DSM repurchased 80,423 shares from 3 to 7 February 2020 at an average price of €113.07.
4 February 2020
DSM repurchased 195,502 shares from 27 to 31 January 2020 at an average price of €110.38.
28 January 2020
DSM repurchased 110,420 shares from 20 to 24 January 2020 at an average price of €111.85.
23 January 2020
Partnership aims to create a longer-term vision for sustainable food systems in Africa.
21 January 2020
DSM repurchased 213,886 shares from 13 to 17 January 2020 at an average price of €109.84.
20 January 2020
As Honorary Chairman Feike Sijbesma will continue to act as DSM's ambassador.
14 January 2020
DSM repurchased 225,888 shares from 6 to 10 January 2020 at an average price of €114.73.
7 January 2020
DSM repurchased 28,011 shares from 2 to 3 January 2020 at an average price of €116.83.
30 December 2019
DSM acquires specialty dairy solutions provider CSK (Koninklijke CSK Food Enrichment C.V.) for about €150 million.
24 December 2019
DSM repurchased 308,286 shares from 16 to 20 December 2019 at an average price of €115.95.
17 December 2019
DSM repurchased 347,955 shares from 9 to 13 December 2019 at an average price of €114.42.
10 December 2019
DSM repurchased 438,649 shares from 2 to 6 December 2019 at an average price of €114.60.
9 December 2019
Thomas Leysen nominated as new Supervisory Board member while Rob Routs, Eileen Kennedy & Pradeep Pant nominated for reappointment.
3 December 2019
DSM repurchased 284,636 shares from 25 to 29 November 2019 at an average price of €117.00.
2 December 2019
CEO Feike Sijbesma will hand over his responsibilities to Managing Board colleagues Geraldine Matchett and Dimitri de Vreeze as Co-CEO’s in February 2020.
26 November 2019
DSM repurchased 445,046 shares from 18 to 22 November 2019 at an average price of €116.60.
19 November 2019
DSM repurchased 428,180 shares from 11 to 15 November 2019 at an average price of €116.15.
18 November 2019
Acquisition strengthens dairy portfolio and application know-how and expertise, particularly in the areas of cheese taste, texture and bio-preservation.
12 November 2019
DSM repurchased 358,500 shares from 4 to 8 November 2019 at an average price of €114.17.
5 November 2019
DSM repurchased 196,255 shares from 28 October to 1 November 2019 at an average price of €107.26.
5 November 2019
DSM reports a good first nine months in 2019 with a solid performance in Q3.
29 October 2019
DSM repurchased 153,111 shares from 21 to 25 October 2019 at an average price of €106.73.
22 October 2019
DSM repurchased 190,019 shares from 14 to 18 October 2019 at an average price of €108.44.
15 October 2019
DSM repurchased 183,500 shares from 7 to 11 October 2019 at an average price of €107.03.
8 October 2019
DSM repurchased 212,170 shares from 30 September to 4 October 2019 at an average price of €107.78.
1 October 2019
DSM repurchased 162,212 shares from 23 to 27 September 2019 at an average price of €106.77.
24 September 2019
DSM repurchased 274,642 shares from 16 to 20 September 2019 at an average price of €108.43
17 September 2019
DSM repurchased 245,676 shares from 9 to 13 September 2019 at an average price of €113.21.
10 September 2019
DSM repurchased 131,289 shares from 2 to 6 September 2019 at an average price of €115.38.
5 September 2019
DSM celebrates 150 years of rich history in social entrepreneurship and biotechnology innovations in the Dutch city of Delft
3 September 2019
DSM repurchased 95,745 shares from 26 to 30 August 2019 at an average price of €110.88.
27 August 2019
DSM repurchased 168,100 shares from 19 to 23 August 2019 at an average price of €110.62.
27 August 2019
JV consists of vitamin E production facilities in Jingzhou and a minority shareholding in Nenter’s intermediates facility in Shishou, China.
20 August 2019
DSM repurchased 276,022 shares from 12 to 16 August 2019 at an average price of €108.76.
13 August 2019
DSM repurchased 263,977 shares from 5 to 9 August 2019 at an average price of €108.13.
6 August 2019
DSM repurchased 131,000 shares from 29 July to 2 August 2019 at an average price of €112.52.
1 August 2019
DSM reports a good H1 2019 and maintains the previously increased full year outlook.
16 July 2019
DSM repurchased 19,871 shares from 8 to 12 July 2019 at an average price of €109.81.
10 July 2019
Veramaris' commercial-scale $200 million facility for production of omega-3 EPA & DHA from natural marine algae opens in Nebraska (US).
9 July 2019
DSM repurchased 41,213 shares from 1 to 5 July 2019 at an average price of €109.50.
2 July 2019
DSM repurchased 150,213 shares from 24 to 28 June 2019 at an average price of €108.69.
1 July 2019
Kazunori Maruyama brings a wealth of experience and will continue to strengthen DSM's second largest business in Asia.
1 July 2019
It is with great sadness that we share the news that our former Managing Board Chairman Simon de Bree has passed away.
28 June 2019
DSM exercises right to redeem all the €300,000,000 1.75% Notes due on 13 November on first optional redemption date of 13 August 2019.
25 June 2019
DSM repurchased 94,194 shares from 17 to 21 June 2019 at an average price of €108.56.
18 June 2019
DSM repurchased 147,395 shares from 10 to 14 June 2019 at an average price of €106.02.
11 June 2019
DSM repurchased 206,267 shares from 3 to 7 June 2019 at an average price of €102.96.
4 June 2019
DSM repurchased 163,903 shares from 27 to 31 May 2019 at an average price of €100.64.
28 May 2019
DSM repurchased 284,500 shares from 20 to 24 May 2019 at an average price of €101.52.
21 May 2019
DSM repurchased 222,500 shares from 13 to 17 May 2019 at an average price of €99.97.
14 May 2019
DSM repurchased 494,782 shares from 6 to 10 May 2019 at an average price of €101.18.
13 May 2019
DSM to acquire leading player in the development, production and sale of specialty materials in India.
8 May 2019
Summary of the resolutions and voting at DSM's Annual General Meeting of Shareholders 2019.
8 May 2019
DSM declares a dividend for the financial year 2018 of €2.30 per ordinary share.
8 May 2019
DSM held its Annual General Meeting of Shareholders on 8 May 2019. Shareholders approved all resolutions on the agenda.
7 May 2019
DSM repurchased 172,159 shares from 29 April to 3 May 2019 at an average price of €100.61.
7 May 2019
DSM reports a good start to the year and increases full year outlook.
30 April 2019
DSM repurchased 165,141 shares from 23 to 26 April 2019 at an average price of €101.54.
23 April 2019
DSM repurchased 123,006 shares from 15 to 18 April 2019 at an average price of €102.40.
16 April 2019
DSM repurchased 229,636 shares from 8 to 12 April 2019 at an average price of €101.48.
9 April 2019
DSM repurchased 144,066 shares from 1 to 5 April 2019 at an average price of €99.84.
3 April 2019
All seven members of the Executive Committee to purchase shares in Royal DSM by converting 50% of their gross STI's into ordinary shares.
26 March 2019
Shareholders to vote on Erica Mann's appointment, and Pauline van der Meer Mohr's re-appointment, as members of DSM's Supervisory Board.
18 March 2019
DSM increases shareholding in Andre Pectin, a leading specialty food ingredient producer of hydrocolloids to 75%.
14 March 2019
€1 billion buy back intended to reduce issued capital, plus a further repurchase of 2,600,000 shares to cover share plans and stock dividend.
13 March 2019
DSM’s targets assessed by Science Based Targets initiative to be in line with the level of decarbonization required to keep global temperature increase below 2° C.
8 March 2019
Report demonstrates DSM’s consistent progress as a growth company with ambitious business and sustainability efforts that creates People, Planet and Profit value.
1 March 2019
50/50 Joint Venture with Cargill will produce zero-calorie, great-tasting sweeteners through fermentation.
14 February 2019
DSM reports a very strong year, including a robust Q4 and increases dividend by 25% from €1.85 to €2.30 per ordinary share.
6 February 2019
At the time DSM's IPO was the biggest introduction in the history of the Amsterdam Stock Exchange.
4 February 2019
DSM will increase its shareholding in Yantai Andre Pectin Co. Ltd. (Andre Pectin), a leading specialty food ingredient producer of hydrocolloids.
31 January 2019
Edith Schippers, who was most recently Minister of Health, Welfare and Sports in the Netherlands who will join DSM on 1st February, replacing Atzo Nicolaï.
31 January 2019
Patricia Malarkey, most recently Head of Research & Development and member of the Executive Committee at Syngenta, will join DSM as Chief Innovation Officer and member of the Executive Committee.
29 January 2019
DSM will create a 75/25 joint venture with Nenter & Co., Inc., which will include all Nenter’s production and related assets for Vitamin E.
17 January 2019
DSM Hydrocolloids strengthens foothold in the industry and unveils new brand identities for its gellan gum and xanthan gum portfolios.
10 January 2019
20.2 MW solar project now largest net-metered solar installation in New Jersey and the second largest on the US East Coast.
14 February 2018
DSM again reports an excellent year, as it significantly exceeded its Strategy 2018 targets for EBITDA, ROCE and organic sales growth.
1 March 2018
The 2017 Integrated Annual Report details the company's progress and performance over the year in terms of People, Planet and Profit.
19 March 2018
DSM intends to repurchase 1,600,000 ordinary shares to cover commitments under share based compensation plans and and part of the final dividend 2017.
23 March 2018
DSM repurchased 136,650 shares from 19 to 22 March 2018 at an average price of €80.59.
30 March 2018
DSM repurchased 188,000 shares from 23 to 29 March 2018 at an average price of €79.38.
6 April 2018
DSM repurchased 87,000 shares from 3 to 5 April 2018 at an average price of €80.10.
12 April 2018
Continued strong organic sales growth in underlying business estimated at 11%. Adjusted EBITDA growth of underlying business estimated at 7% despite significant FX headwind. Additional temporary vitamin price benefit estimated at €165m on Adjusted EBITDA. Overall very strong quarter with total Adjusted EBITDA up 55%.
13 April 2018
DSM repurchased 88,350 shares from 6 to 12 April 2018 at an average price of €81.74.
8 May 2018
Royal DSM issues its full Q1 2018 results, which are in line with the preliminary figures for Q1 2018 previously announced on 12 April 2018.
9 May 2018
DSM held its Annual General Meeting of Shareholders on 9 May 2018. Shareholders approved all resolutions on the agenda.
9 May 2018
DSM declares a dividend for the financial year 2017 of €1.85 per ordinary share.
18 May 2018
DSM and CVC Capital Partners indirectly own 35% and 65% respectively of the shares of Fibrant BV through Chemicalnvest joint venture.
18 May 2018
DSM repurchased 91,500 shares from 14 to 17 May 2018 at an average price of €87.39.
30 May 2018
DSM repurchased 176,500 shares from 18 to 24 May 2018 at an average price of €88.02.
30 May 2018
DSM has linked the interest rate of new €1 billion Revolving Credit Facility to its performance on the reduction of GHG emissions.
1 June 2018
DSM repurchased 233,975 shares from 25 to 31 May 2018 at an average price of €86.30.
12 June 2018
DSM repurchased 141,033 shares from 1 to 7 June 2018 at an average price of €88.22.
15 June 2018
DSM repurchased 132,098 shares from 8 to 14 June 2018 at an average price of €89.07.
20 June 2018
With its unique science-based competences, DSM is ideally positioned to capture the growth opportunities offered by the global megatrends and Sustainable Development Goals (SDGs), with a particular focus on Nutrition & Health, Climate & Energy and Resources & Circularity.
22 June 2018
DSM repurchased 324,894 shares from 15 to 20 June 2018 at an average price of €88.18, concluding program to repurchase 1,600,000 shares for a total of €136.7 million.
20 March 2018
Companies signed two long-term power purchase agreements (PPAs) that enabled construction of two windfarm projects.
31 May 2018
AIF’s plant in Kigali has an annual production capacity of 45,000 tons making it one of the largest nutrition factory sites on the continent and it works with over 9,000 farmers across Rwanda and produces meals for 1.5 million people every day.
7 June 2018
From 2018 all DSM's purchased electricity in the Netherlands will come from renewable sources, thanks to an agreement with Dutch energy supplier Eneco.
9 October 2018
DSM has extended its partnership with the World Food Programme by 3 years to continue fighting hidden hunger and enabling better nutrition for vulnerable people.
25 October 2018
Improving society’s ability to adapt to a changing climate.
29 June 2018
Bain Capital intends to acquire DSM Sinochem Pharmaceuticals, a DSM and Sinochem Group 50/50 joint venture, with the transaction expected to be completed in the fourth quarter of 2018 subject to customary regulatory approvals and consultations.
2 July 2018
Acquisition builds on partnership combining DSM’s unparalleled expertise in micronutrients with Mixfit technology.
1 August 2018
DSM reports a very good H1 with strong performance across all businesses.
13 August 2018
DSM intends to repurchase 1,100,000 ordinary shares: 500,000 to cover commitments under share-based compensation plans and 600,000 to cover part of the interim dividend 2018.
21 August 2018
DSM repurchased 215,656 shares from 13 to 17 August 2018 at an average price of €89.80.
23 August 2018
DSM named on Fortune Magazine’s ‘Change the World’ List for third consecutive year and again ranked number 1 globally in sustainability by Sustainalytics
28 August 2018
DSM repurchased 82,975 shares from 20 to 24 August 2018 at an average price of €89.58.
4 September 2018
DSM repurchased 117,471 shares from 27 to 31 August 2018 at an average price of €91.17.
11 September 2018
DSM repurchased 189,309 shares from 3 to 7 September 2018 at an average price of €88.16.
13 September 2018
DSM recognized among the DJSI leaders for 15 years running and held the number one position in the sector eight times.
18 September 2018
DSM repurchased 94,032 shares from 10 to 14 September 2018 at an average price of €88.38.
25 September 2018
DSM repurchased 69,638 shares from 17 to 21 September 2018 at an average price of €91.24.
2 October 2018
DSM repurchased 121,592 shares from 24 to 28 September 2018 at an average price of €91.88.
9 October 2018
DSM repurchased 209,327 shares from 1 to 5 October 2018 at an average price of €90.13, finalizing program to repurchase 1,100,000 shares for a total of €98.9 million.
12 October 2018
Ertharin Cousin, former Executive Director of the United Nations World Food Programme, has joined DSM's Sustainability Advisory Board.
30 October 2018
DSM anticipates receiving about €200 million in cash in various steps in 2018 and 2019.
31 October 2018
DSM reports another very good quarter and is confident in achieving full year outlook.
31 October 2018
Bain Capital completes acquisition of DSM Sinochem Pharmaceuticals from DSM and Sinochem, both of whom held an equity stake of 50%.
8 November 2018
Companies to produce highly sought-after molecules such as steviol glycosides Reb M and Reb D through fermentation.
9 May 2018
Summary of the resolutions and voting at DSM's Annual General Meeting of Shareholders 2018.
29 December 2017
Sale of Amyris Brasil Ltda to DSM and the establishment of a long-term manufacturing partnership for Amyris’s high-volume products finalized.
22 December 2017
DSM expands its offering in gut health ingredients with probiotics, an attractive market segment in nutritional ingredients, growing an estimated 7% per year.
11 December 2017
Call for framework conditions laying foundation for a pathway to limiting global temperature rise to well below 2° Celsius and allow them to actively contribute to the implementation of the Paris Agreement.
7 December 2017
Report details how four major corporate renewable energy buyers came together to successfully aggregate demand and jointly sign multiple wind power PPAs in Europe.
17 November 2017
DSM and Amyris enhance their strategic alliance through the sale of Amyris Brasil Ltda to DSM and the establishment of a long-term manufacturing partnership for Amyris’ high-volume products.
17 November 2017
DSM repurchased 151,900 shares from 10 to 14 November 2017 at an average price of €75.63, concluding program to repurchase 1,600,000 shares for a total of €109.3 million.
13 November 2017
DSM positioned to outpace its global target of 50% purchased electricity from renewable sources by 2025.
10 November 2017
DSM and Haixing will be able to expand their global business of sustainable and innovative hydrocolloid solutions applied in food, beverage and personal care products to provide texture and stability.
10 November 2017
DSM repurchased 243,624 shares from 3 to 9 November 2017 at an average price of €76.15.
2 November 2017
Strong performance in Q3 2017, contributing to very good first nine months.
30 October 2017
Partnership to focus on reaching mothers and children with nutrition interventions during the crucial first 1,000 days of children’s lives, from conception to age 2.
9 October 2017
DSM repurchased 37,600 shares from 6 to 12 October 2017 at an average price of €69.54.
6 October 2017
DSM repurchased 140,692 shares from 29 September to 5 October 2017 at an average price of €69.52.
29 September 2017
On 27 September 2017 a fatal accident took place at DSM's site in Augusta (GA, US), in which a contractor sadly lost his life and two others injured, and expected to recover.
29 September 2017
DSM repurchased 163,310 shares from 22 to 28 September 2017 at an average price of €67.75.
25 September 2017
EBITDA and ROCE outlook for 2017 confirmed. DSM aims to continue to deliver against its strategic targets in 2018. DSM brings forward its regular strategic review process for the period beyond 2018 and expects to share the conclusions before the summer of 2018.
22 September 2017
DSM repurchased 117,424 shares from 15 to 21 September 2017 at an average price of €66.56.
22 September 2017
Twilmij’s core values, customer portfolio and solutions are a perfect fit with DSM’s ambitions in the animal nutrition & health market.
15 September 2017
DSM repurchased 128,851 shares from 8 to 14 September 2017 at an average price of €66.04.
11 September 2017
DSM in 2nd place in Fortune Magazine’s 3rd annual Change the World list, which recognizes 56 companies that have had a positive social impact through activities that are part of their core business strategy.
8 September 2017
DSM repurchased 142,315 shares from 1 to 7 September 2017 at an average price of €65.01.
7 September 2017
DSM again named among worldwide leaders in the Materials industry group in the Dow Jones Sustainability World Index having been named among the global leaders for the past 14 years and holding the number one position in the sector seven times, including last year.
1 September 2017
DSM repurchased 188,430 shares from 25 to 31 August 2017 at an average price of €64.01.
1 September 2017
It is with great sadness that we share the news that our friend and former colleague, Peter Elverding has passed away.
29 August 2017
Thermo Fisher Scientific Inc. has completed the acquisition of Patheon N.V. (NYSE:PTHN), a company in which DSM held approximately 48.7 million ordinary shares.
25 August 2017
DSM repurchased 185,837 shares from 18 to 24 August 2017 at an average price of €63.98.
18 August 2017
DSM repurchased 100,017 shares from 14 to 17 August 2017 at an average price of €63.21.
14 August 2017
DSM intends to repurchase 1,600,000 ordinary shares to cover commitments under management and personnel option plans and for part of the interim dividend 2017.
1 August 2017
DSM maintained its positive momentum with a very strong first half-year performance with Q2 another very good quarter.
21 July 2017
Judith Wiese will join DSM as Executive Vice President Group People & Organization on 1 October 2017.
14 July 2017
DSM repurchased 261,898 shares from 7 to 13 July 2017 at an average price of €63.24, concluding program to repurchase 2,900,000 shares for a total of €187.2 million.
7 July 2017
DSM repurchased 218,403 shares from 30 June to 6 July 2017 at an average price of €63.72.
30 June 2017
DSM repurchased 182,175 shares from 23 to 29 June 2017 at an average price of €65.07.
23 June 2017
DSM repurchased 122,307 shares from 16 to 22 June 2017 at an average price of €67.16.
16 June 2017
DSM repurchased 123,435 shares from 9 to 15 June 2017 at an average price of €66.00.
13 June 2017
Support from DSM and global partners to scale-up 100% renewable energy solution.
9 June 2017
DSM repurchased 132,717 shares from 2 to 8 June 2017 at an average price of €65.73.
2 June 2017
DSM repurchased 123,673 shares from 26 May to 1 June 2017 at an average price of €66.16.
29 May 2017
AIF Rwanda now producing highly nutritious porridge flours (with added milk, vitamins and minerals) targeting vulnerable population segments such as pregnant and breast-feeding mothers, older infants and young children in the first 1,000 days of their lives.
26 May 2017
DSM repurchased 123,847 shares from 19 to 25 May 2017 at an average price of €66.10.
19 May 2017
DSM repurchased 139,447 shares from 12 to 18 May 2017 at an average price of €66.66.
15 May 2017
Thermo Fisher will commence a tender offer to acquire all of the issued and outstanding shares of Patheon for $35.00 per ordinary share in cash.
12 May 2017
DSM repurchased 128,958 shares from 5 to 11 May 2017 at an average price of €65.76.
8 May 2017
DSM to make equity investment in Amyris and the companies to enter development cooperation focused on products for the health and nutrition markets.
5 May 2017
DSM repurchased 114,048 shares from 28 April to 4 May 2017 at an average price of €66.44.
3 May 2017
DSM declares a dividend for the financial year 2016 of €1.75 per ordinary share.
3 May 2017
DSM held its Annual General Meeting of Shareholders on 3 May 2017. Shareholders approved all resolutions on the agenda.
3 May 2017
Summary of the resolutions at DSM'S Annual General Meeting of Shareholders 2017.
28 April 2017
DSM repurchased 126,540 shares from 21 to 27 April 2017 at an average price of €65.81.
21 April 2017
DSM repurchased 75,948 shares from 18 to 20 April 2017 at an average price of €65.02.
14 April 2017
DSM repurchased 126,073 shares from 7 to 13 April 2017 at an average price of €65.16.
12 April 2017
Finalists selected from ten best science and entrepreneurial team submissions.
7 April 2017
DSM repurchased 134,338 shares from 31 March to 6 April 2017 at an average price of €64.04.
3 April 2017
New state-of-the-art biotechnology facility will accelerate DSM’s biotechnology research and development capabilities for applications in food and nutrition, feed, fuel, pharma and bio-based materials.
31 March 2017
DSM repurchased 235,605 shares from 24 to 30 March 2017 at an average price of €62.81.
24 March 2017
DSM repurchased 308,025 shares from 17 to 23 March 2017 at an average price of €62.12.
21 March 2017
DSM proposes re-appointment of Dimitri de Vreeze the Managing Board and appointment of John Ramsay and Frits van Paasschen to the Supervisory Board.
17 March 2017
DSM repurchased 222,563 shares from 13 to 16 March 2017 at an average price of €62.92 for a total of €14.0 million.
13 March 2017
DSM to repurchase 2,900,000 ordinary shares to cover commitments under management and personnel option plans and for part of final dividend 2016.
3 March 2017
2016 Integrated Annual Report, in which DSM reports on its progress and performance over the year in terms of People, Planet and Profit, published on 3 March 2017.
16 February 2017
Plant has achieved 70 gallon per ton conversion rate and POET-DSM Advanced Biofuels will now build an on-site enzyme manufacturing facility in Emmetsburg, Iowa, pending state and local approvals.
15 February 2017
DSM reports a very good 2016 in which it achieved strong EBITDA and ROCE growth, well ahead of the mid-term targets set out in its Strategy 2018: Driving Profitable Growth.
14 February 2017
DSM updates way its financial results are presented starting with Q4/full-year results for 2016, following recent changes to accounting and reporting guidelines in Europe.
23 January 2017
Robin Chase, cofounder and former CEO of Zipcar, member of Boards of Veniam, World Resources Institute and Tucows and advisor to French National Digital Agency and USDOT’s Advisory Committee on Automated Transportation, joins DSM's Sustainability Advisory Board.
9 December 2016
DSM repurchased 361,907 shares from 2 to 8 December 2016 at an average price of €56.21 and concluded the program to repurchase 1,700,000 shares.
2 December 2016
DSM repurchased 215,424 of its own shares from 25 November to 1 December 2016 at an average price of €57.32.
25 November 2016
DSM repurchased 248,036 shares from 18 to 24 November 2016 at an average price of €57.14.
22 November 2016
DSM announces the departure of Managing Board and Executive Committee member Stephan B. Tanda as of 1 February 2017.
18 November 2016
DSM repurchased 360,149 shares from 11 to 17 November 2016 at an average price of €56.21.
11 November 2016
DSM repurchased 514,484 shares from 4 to 10 November 2016 at an average price of €56.17.
4 November 2016
DSM intends to repurchase up to 1,700,000 ordinary shares in order to cover its commitments under management and personnel option plans.
19 September 2016
DSM announces the successful launch of a €750 million bond, with a ten-year maturity due in 2026, at a coupon of 0.75%.
8 September 2016
DSM has been named the worldwide leader in the Materials industry group in the Dow Jones Sustainability World Index 2016.
27 July 2016
DSM announces the successful completion of its secondary offering of 4,761,905 ordinary shares in Patheon N.V. in connection with Patheon N.V.’s Initial Public Offering of ordinary shares.
22 July 2016
DSM repurchased 83,073 shares from 15 to 21 July 2016 at an average price of €56.75 and concluded the program to repurchase 3,500,000 shares.
21 July 2016
Patheon N.V., a company in which DSM holds approximately 53.5 million ordinary shares, has priced its Initial Public Offering at USD 21.00 per ordinary share.
15 July 2016
DSM repurchased 107,432 shares from 8 to 14 July 2016 at an average price of €54.67.
11 July 2016
Patheon N.V., a company in which DSM holds approximately 53.5 million ordinary shares, has today commenced an Initial Public Offering.
8 July 2016
DSM repurchased 95,055 shares from 1 to 7 July 2016 at an average price of €52.09.
1 July 2016
DSM repurchased 248,553 shares from 24 to 30 June 2016 at an average price of €50.64.
30 June 2016
Protective properties of the bib-shorts are further enhanced by a new and optimized design of the Dyneema fabric.
24 June 2016
DSM repurchased 115,202 shares from 17 to 23 June 2016 at an average price of €53.57.
17 June 2016
DSM repurchased 125,684 shares from 10 to 16 June 2016 at an average price of €53.20.
10 June 2016
DSM intends to increase the running share repurchase program by an additional 300,000 shares to a total of 3,500,000 to cover the interim stock dividend 2016.
3 June 2016
DSM repurchased 151,361 shares from 27 May to 2 June 2016 at an average price of €54.46.
27 May 2016
DSM repurchased 152,420 shares from 20 to 26 May 2016 at an average price of €53.26
20 May 2016
DSM repurchased 152,511 shares from 13 to 19 May 2016 at an average price of €52.54.
13 May 2016
DSM repurchased 153,360 shares from 6 to 12 May 2016 at an average price of €52.27.
6 May 2016
DSM repurchased 153,694 shares from 29 April to 5 May 2016 at an average price of €52.34.
3 May 2016
DSM provides an update on the development of its Nutrition organization and several key positions to further support its growth plans.
29 April 2016
DSM held its Annual General Meeting of Shareholders on 29 April 2016. Shareholders approved all resolutions on the agenda.
29 April 2016
Summary of the resolutions at DSM'S Annual General Meeting of Shareholders 2016.
29 April 2016
DSM repurchased 163,523 shares from 22 to 28 April 2016 at an average price of €53.25.
29 April 2016
DSM declares a dividend for the financial year 2015 of €1.65 per ordinary share of €1.50 nominal value.
22 April 2016
DSM repurchased 153,579 shares from 15 to 21 April 2016 at an average price of €52.05.
15 April 2016
DSM repurchased 153,992 shares from 8 to 14 April 2016 at an average price of €50.01.
8 April 2016
DSM repurchased 167,229 shares from 1 to 7 April 2016 at an average price of €47.8951.
1 April 2016
DSM repurchased 93,033 shares from 29 to 31 March 2016 at an average price of €48.5712.
31 March 2016
All members of the Executive Committee purchase ordinary shares in Royal DSM, expressing their confidence in the growth prospects of the company.
25 March 2016
DSM repurchased 159,637 shares from 18 to 24 March 2016 at an average price of €48.28.
18 March 2016
DSM repurchased 161,667 shares from 11 to 17 March 2016 at an average price of €48.06.
11 March 2016
DSM repurchased 232,331 shares from 4 to 10 March 2016 at an average price of €47.13.
4 March 2016
DSM repurchased 269,930 shares from 26 February to 3 March 2016 at an average price of €45.84.
1 March 2016
DSM announces the publication of its 2015 Integrated Annual Report.
26 February 2016
DSM repurchased 267,680 shares from 22 to 25 February 2016 at an average price of €43.94.
25 February 2016
Ndidi Okonkwo Nwuneli, founder of LEAP Africa and co-founder of AACE Food Processing & Distribution Ltd and partner at Sahel Capital, an advisory and private equity firm, has joined DSM's Sustainability Advisory Board.
22 February 2016
DSM to repurchase 3,200,000 ordinary shares to cover commitments under management and personnel option plans and as part of the final dividend 2015.
17 February 2016
Q4 Group net sales up 6% to €1,926m and EBITDA up 3% to €261m.
7 January 2016
At the Annual General Meeting of Shareholders the Supervisory Board will nominate Mr. Pradeep Pant for appointment as a member of DSM's Supervisory Board.
17 December 2015
DSM and the United Nations World Food Programme sign agreement extending their existing partnership to combat hidden hunger and malnutrition in the developing world to 2018.
6 November 2015
DSM and Syngenta R&D partnership to develop microbial-based agricultural solutions, including bio-controls, bio-pesticides and bio-stimulants.
4 November 2015
After a period of transformation, DSM will focus on improving its financial results through organic growth, reducing costs and strict capital allocation.
3 November 2015
Sales up 8%, driven by 7% organic growth in Nutrition and foreign exchange.
30 October 2015
DSM awarded FD-Henri Sijthoff prize for the best annual report by a company listed on the AEX stock exchange in the Netherlands for its 2014 Integrated Annual Report.
15 September 2015
DSM successfully issued a €500 million 1.375% bond due 2022.
10 September 2015
DSM named among the worldwide leaders in the Materials industry group in the Dow Jones Sustainability World Index 2015.
27 August 2015
Eurobike Award is a fantastic recognition of a breakthrough development that greatly benefits professional and amateur riders alike.
25 August 2015
Adjustments to organizational and operating model aim to create more agile, focused and cost efficient organization, with a stronger business and market focus and globally leveraged support functions.
4 August 2015
Solid sales performance with a 12% increase to €1,965 million, supported by foreign exchange rates and 3% volume growth.
31 July 2015
Partnership finalized for DSM’s activities in Polymer Intermediates (Caprolactam & Acrylonitrile) and Composite Resins with formation of ChemicaInvest B.V..
29 July 2015
DSM repurchased 204,254 shares from 24 to 28 July 2015 at an average price of €52.44 and concluded the program to repurchase 2,300,000 shares.
24 July 2015
DSM repurchased 184,648 shares from 17 to 23 July 2015 at an average price of €54.52.
17 July 2015
DSM repurchased 74,088 shares from 10 to 16 July 2015 at an average price of €53.54.
10 July 2015
DSM repurchased 190,870 shares from 3 to 9 July 2015 at an average price of €51.34.
3 July 2015
DSM repurchased 362,143 shares from 26 June to 2 July 2015 at an average price of €53.03.
1 July 2015
Shorts feature new fabric with Dyneema® fiber to provide increased protection to the thigh in the event of a crash.
26 June 2015
DSM repurchased 245,123 shares from 19 to 25 June 2015 at an average price of €53.87.
24 June 2015
DSM begins debate on the contribution of science to society: www.sciencecanchangetheworld.org.
19 June 2015
DSM repurchased 223,561 shares from 12 to 18 June 2015 at an average price of €52.87.
12 June 2015
DSM repurchased 185,315 shares from 5 to 11 June 2015 at an average price of €53.36.
5 June 2015
DSM repurchased 277,686 shares from 29 May to 4 June 2015 at an average price of €53.95.
29 May 2015
DSM repurchased 128,219 shares from 22 to 28 May 2015 at an average price of €53.8102.
22 May 2015
DSM repurchased 224,093 shares from 18 to 21 May 2015 at an average price of €53.18.
14 May 2015
DSM intends repurchasing 2,300,000 ordinary shares in order to cover its commitments under management and personnel option plans.
30 April 2015
DSM declares dividend for the financial year 2014 of €1.65 per ordinary share.
30 April 2015
DSM held its Annual General Meeting of Shareholders on 30 April 2015. Shareholders approved all resolutions on the agenda.
30 April 2015
Summary of the resolutions at DSM'S Annual General Meeting of Shareholders 2015.
29 April 2015
Sales of €1,886 million, up 11%, including 2% organic sales growth.
2 April 2015
DSM Synres produced solvent-borne alkyd and acrylic coating resins for the global coatings, adhesives and graphic arts markets.
2 April 2015
Figures reflect reclassification of Polymer Intermediates cluster and DSM Composite Resins to discontinued operations. Corporate Activities are restated and also reflect the sale of DSM Synres.
1 April 2015
DSM has successfully issued a €500 million 1.0% bond due 2025.
31 March 2015
DSM finalizes acquisition of Aland, a Hong Kong-based company producing vitamin C in mainland China.
18 March 2015
DSM proposes re-appointment of Stephan B. Tanda and announces departure of Stefan Doboczky as of 1 June 2015.
16 March 2015
Partnership for DSM’s activities in Polymer Intermediates (Caprolactam and Acrylonitrile) and Composite Resins with formation of new company 65% owned by CVC and 35% by DSM.
3 March 2015
Euroresins, a distributor of products to the composite resins industry, sold to Cathay Investments.
3 March 2015
DSM announces publication of 2014 Integrated Annual Report.
11 February 2015
Sales of €9,181 million, a 4% increase versus 2013. In line with market expectations, DSM reported EBITDA of €1,168 million compared to €1,261 million in 2013.
5 January 2015
Partnership aimed at enabling Team Giant-Alpecin to benefit from DSM's innovative power.
23 December 2014
DSM has reached agreement with Cathay Investments for the sale of Euroresins and the transaction is expected to close in Q1 2015.
17 December 2014
DSM has reached agreement with Standard Investment for the sale of DSM Synres and the transaction is expected to close in Q1 2015.
5 November 2014
DSM provides investors with update on its strategic progress and current priorities at annual Capital Markets Day.
4 November 2014
Third quarter 2014 EBITDA from continuing operations of €315 million compared to €293 million in Q2 2014 and €331 million in Q3 2013.
11 September 2014
DSM named among the worldwide leaders in the Materials industry group in the Dow Jones Sustainability World Index 2014.
3 September 2014
POET-DSM Advanced Biofuels proves its revolutionary technology that converts agricultural residue into renewable fuel at opening of its first commercial cellulosic ethanol plant.
5 August 2014
DSM's second quarter 2014 EBITDA from continuing operations of €293 million compared to €332 million in Q2 2013, and €272 million in Q1 2014.
11 July 2014
DSM reaches agreement to acquire Aland, a Hong Kong-based company producing vitamin C in mainland China.
2 July 2014
Production of a few intermediates, mainly for Animal Nutrition & Health interrupted. Impact on customers expected to be minimal.
20 May 2014
DSM repurchased 69,522 shares from 16 to 19 May 2014 at an average price of €51.67 and concluded the program to repurchase 5,000,000 shares.
16 May 2014
DSM repurchased 176,832 shares from 9 to 15 May 2014 at an average price of €51.97.
9 May 2014
DSM repurchased 294,921 shares from 2 to 8 May 2014 at an average price of €52.03.
7 May 2014
DSM declares dividend for the financial year 2013 of €1.65 per ordinary share.
7 May 2014
DSM held its Annual General Meeting of Shareholders on 7 May 2014. Shareholders approved all resolutions on the agenda.
7 May 2014
Summary of the resolutions at DSM'S Annual General Meeting of Shareholders 2014.
6 May 2014
DSM reports first quarter EBITDA from continuing operations of €272 million compared to €301 million in Q1 2013.
2 May 2014
DSM repurchased 201,426 shares from 25 to 30 April 2014 at an average price of €51.49.
25 April 2014
DSM repurchased 170,120 shares from 22 to 24 April 2014 at an average price of €50.42.
18 April 2014
DSM repurchased 231,586 shares from 11 to 17 April 2014 at an average price of €49.15.
11 April 2014
DSM repurchased 256,801 shares from 4 to 10 April 2014 at an average price of €50.17.
9 April 2014
DSM in exclusive discussions with Aland that may or may not result in the acquisition of this China-based global producer of vitamin C.
4 April 2014
DSM repurchased 149,321 shares from 28 March to 3 April 2014 at an average price of €50.05.
28 March 2014
DSM repurchased 157,579 shares from 21 to 27 March 2014 at an average price of €48.46.
21 March 2014
DSM repurchased 108,500 shares from 14 to 20 March 2014 at an average price of €46.51.
14 March 2014
DSM repurchased 254,756 shares from 7 to 13 March 2014 at an average price of €47.40.
11 March 2014
USD 2.65 billion transaction to create global CDMO leader successfully completed.
10 March 2014
DSM to appoint Geraldine Matchett as Member of the Managing Board of Directors as of 1 August 2014 and as of 1 December 2014, she will become Chief Financial Officer.
7 March 2014
DSM repurchased 428,636 shares from 27 February to 6 March 2014 at an average price of €46.54.
28 February 2014
DSM issues €500 million 2.375% bond due 2024.
27 February 2014
DSM intends to repurchase of 2,500,000 ordinary shares to cover commitments under management and personnel option plans.
26 February 2014
For full year 2013 DSM delivered 18% higher EBITDA while facing challenging economic environment. In Q4 the company realized 30% higher EBITDA.
23 January 2014
DSM repurchased 874,725 shares from 17 January 2014 up to and including 21 January 2014 at an average price of €51.85 and concludes first part of program to repurchase 4-5 million shares in total.
21 January 2014
DSM delivered roughly 20% higher EBITDA for the full year 2013, in spite of the challenging economic environment and in Q4 realized an approximately 30% higher EBITDA.
17 January 2014
DSM repurchased 245,742 shares from 10 to 16 January 2014 at an average price of €56.90.
10 January 2014
DSM repurchased 112,588 shares from 6 to 9 January 2014 at an average price of €57.88.
20 December 2013
DSM repurchased 154,586 shares from 13 to 19 December 2013 at an average price of €55.35.
18 December 2013
Final Terms of the €300,000,000 1.75% Notes due 13 November 2019 adjusted to reflect investors have a put option in the event of a change of control.
13 December 2013
DSM repurchased 185,761 shares from 6 to 12 December 2013 at an average price of €56.08.
6 December 2013
DSM repurchased 164,545 shares from 29 November to 5 December 2013 at an average price of €57.17.
4 December 2013
Award recognizes DSM's global corporate leadership in efforts to mitigate food insecurity, prevent hidden hunger and promote sustainable development in low-income countries.
21 November 2013
DSM repurchased 346.038 shares from 15 to 21 November 2013 at an average price of €59.06.
21 November 2013
DSM repurchased 198,288 shares from 22 to 28 November 2013 at an average price of €58.39.
19 November 2013
Global CDMO company combines DSM Pharmaceutical Products and Patheon.
15 November 2013
DSM repurchased 217,727 shares from 6 to 14 November 2013 at an average price of €58.05.
6 November 2013
DSM successfully issues €300 million 1.75% bond due 2019.
6 November 2013
DSM intends to repurchase 2,500,000 ordinary shares to cover commitments under management and personnel option plans.
5 November 2013
Q3 EBITDA of €342 million compared to €270 million in Q3 2012. 27% improvement realized despite ongoing challenging macro-economic environment.
9 October 2013
DSM acquires 19% equity interest in Yantai Andre Pectin Co. Ltd., a China based producer of texturing ingredients.
26 September 2013
DSM providing review of strategic progress and update on its 2015 targets at its annual Capital Markets Day.
12 September 2013
DSM once again amongst leaders in chemical industry sector in Dow Jones Sustainability World Index 2013.
6 August 2013
DSM reports second quarter EBITDA of €345 million compared to €290 million in Q2 2012 and €311 million in Q1 2013.
1 July 2013
DSM acquires Unitech Industries Limited, a New Zealand based producer of nutritional products for both human and animal markets.
11 June 2013
Feike Sijbesma joins Global CEO Council (GCC) of the Chinese People’s Association for Friendship with Foreign Countries (CPAFFC).
8 June 2013
DSM to help provide effective nutrition interventions to 50 million pregnant and lactating woman and children under two per year by 2020 as part of DSM’s endorsement of Global Nutrition for Growth Compact.
22 May 2013
Working together to achieve lasting progress in global health and development by improving the nutritional status of mothers and children.
7 May 2013
Agreement to acquire 19% equity interest in Yantai Andre Pectin Co. Ltd. (Andre Pectin), a China based producer of texturing ingredients.
3 May 2013
DSM declares a dividend for the financial year 2012 of €1.50 per ordinary share of €1.50 nominal value.
3 May 2013
DSM held its Annual General Meeting of Shareholders on 3 May 2013. Shareholders approved all resolutions on the agenda.
3 May 2013
Summary of the resolutions at DSM's Annual General Meeting of Shareholders 2013.
2 May 2013
DSM reports first quarter EBITDA of €311 million compared to €306 million in Q1 2012 and €243 million in Q4 2012.
8 April 2013
Strategic partnership with Rostekhnologii (Rostec) in fields of biotechnology and functional materials.
8 April 2013
Partnership with Ministry of Health Care of the Republic of Tatarstan aims to modernize the Republic’s public health sector through fortified nutrition.
8 April 2013
DSM acquires Tortuga, a nutritional supplements company with a focus on pasture raised beef and dairy cattle for a total enterprise value of about €440 million.
14 March 2013
DSM proposes appointing Mr. Dimitri de Vreeze to the Managing Board effective 1 September 2013.
4 March 2013
DSM sells its participation in DEXPlastomers, a 50/50 Joint Venture of DSM with affiliate of ExxonMobil Chemical, to Borealis.
20 February 2013
DSM delivered growth across all clusters in 2012 excluding caprolactam. Nutrition represents more than 70% of total EBITDA and become high value, global business with attractive growth prospects across the full value chain.
24 January 2013
Agreement extends existing partnership to 2015 to combat hidden hunger and malnutrition in the developing world.
12 December 2012
Award recognizes DSM's integrated Triple P approach to creating a sustainable business and shared value with all stakeholders.
7 December 2012
University of Maastricht confers honor on Feike Sijbesma because of way he embodies DSM’s core value, sustainability.
6 December 2012
Acquisition enables DSM to become a global tier one dairy ingredients supplier.
28 November 2012
DSM awarded Sustainable Supply Chain Award 2012 for its responsible way of managing its supply chain.
23 November 2012
DSM receives three prestigious awards in the Netherlands for its 2011 Integrated Annual Report.
12 November 2012
Agreement with Borealis AG reached for sale of DEXPlastomers V.o.F and DSM's LldPE Compact Solution Technology.
6 November 2012
DSM continues to generate good results mainly driven by Nutrition cluster and make good progress towards strategic goals with purchase of Tortuga and Cargill’s cultures and enzymes business.
26 October 2012
DSM to acquire Cargill’s cultures and enzymes business in an all cash transaction for a total enterprise value of €85 million.
27 September 2012
DSM updates financial community at its annual Capital Markets Days on progress made with its DSM in Motion: driving focused growth strategy.
20 September 2012
Chris Goppelsroeder appointed President and CEO DSM Nutritional Products effective 1 January 2013.
20 September 2012
DSM in exclusive discussions with Cargill which may, or may not result in DSM's acquisition of Cargill’s cultures and enzymes business.
13 September 2012
DSM again among leaders in chemical industry sector in the Dow Jones Sustainability World Index 2012.
8 August 2012
Definitive agreement to acquire Tortuga Companhia Zootécnica Agrária (Tortuga) in all cash transaction for total enterprise value of about €465 million.
7 August 2012
Life Sciences cluster accounts for around 70% of Q2 EBITDA offsetting weakness caused by caprolactam in Materials Sciences. Other Materials Sciences businesses improve.
19 July 2012
DSM acquires Ocean Nutrition Canada, leading global provider of fish-oil derived nutritional products to dietary supplement and food and beverage markets for a total enterprise value of C$540 million.
25 June 2012
DSM completes acquisition of Kensey Nash for a total enterprise value of approximately $360 million.
19 June 2012
Tender offer to purchase all outstanding shares of common stock of Kensey Nash Corporation at a price of $38.50 per share successful.
6 June 2012
Expiration of mandatory waiting period under Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, for previously announced tender offer for all outstanding shares of common stock of Kensey Nash Corporation.
5 June 2012
DSM qualified as supplier of enzymes for DONG Energy - Inbicon’s wheat straw to cellulosic ethanol process.
21 May 2012
DSM commences previously announced tender offer for all outstanding shares of common stock of Kensey Nash at a price of $38.50 per share.
18 May 2012
Definitive agreement with Clearwater Fine Foods and funds managed by Richardson Capital to acquire Ocean Nutrition Canada for a total enterprise value of C$540 million.
11 May 2012
Annual General Meeting of Shareholders approves appointing Mrs. Victoria Haynes and Mrs. Eileen Kennedy as Supervisory Board members.
11 May 2012
DSM declares a dividend for 2011 of €1.45 per ordinary share of €1.50 par value.
11 May 2012
DSM held its Annual General Meeting of Shareholders on 11 May 2012. Shareholders approved all resolutions on the agenda.
11 May 2012
Summary of the resolutions at DSM's Annual General Meeting of Shareholders 2012.
8 May 2012
In a challenging business environment, DSM continued to make good progress in Q1 and the robust results represent a positive start to 2012.
3 May 2012
DSM will acquire all outstanding shares of common stock of Kensey Nash through a cash tender offer, followed by a merger with a subsidiary of DSM, for $38.50 in cash per share for total enterprise value of approximately $360 million.
1 May 2012
Jos Op Heij new Senior Vice President Corporate Control and Accounting, Hans Vossen new VP Corporate Treasury & Dave Huizing new VP Investor Relations.
26 March 2012
DSM acquires certain assets, licenses and other agreements in the area of food enzymes and oilseed processing from Verenium for a total consideration including transaction and related expenses of $37 million.
29 February 2012
2011 was another strong year for DSM despite challenges of global economy, adverse currency movements and high raw material costs and increases dividend for second consecutive year.
14 February 2012
Cees Los joins DSM as General Counsel and Director Legal Affairs as of 15 April 2012.
23 January 2012
Joint Venture to commercially demonstrate and license cellulosic bio-ethanol, the next step in the development of biofuels, based on their proprietary and complementary technologies.
26 November 2011
Q3 2011 EBITDA from continuing operations €339 million, 26% ahead of Q3 2010, outlook remains unchanged: 2011 is expected to be a strong year with further progress towards achieving 2013 targets.
3 November 2011
DSM repurchased 502,990 shares from 27 October to 2 November 2011 at an average price of €37.33 and concluded the program to repurchase 4,000,000 shares.
27 October 2011
DSM repurchased 471,588 shares from 20 to 26 October 2011 at an average price of €36.81.
27 October 2011
TCG developed OtCM™ system to monitor compliance with drug therapy.
20 October 2011
DSM repurchased 545,760 shares from 13 to 19 October 2011 at an average price of €37.15.
13 October 2011
DSM repurchased 391,817 shares from 6 to 12 October 2011 at an average price of €35.51.
11 October 2011
DSM Supervisory Board proposes appointing Mrs. Victoria Haynes and Mrs. Eileen Kennedy as Supervisory Board members.
6 October 2011
DSM repurchased 519,526 shares from 29 September to 5 October 2011 at an average price of €32.42.
30 September 2011
DSM acquires Shandong ICD High Performance Fiber Co. Ltd. (ICD), based in Laiwu, Shandong province, China.
29 September 2011
DSM updates investment community on progress made with strategy marking the shift from an era of intensive portfolio transformation to a strategy for the coming years of maximizing sustainable and profitable growth of ‘the new DSM’.
29 September 2011
DSM repurchased 523,199 shares from 22 to 28 September 2011 at an average price of €31.49.
29 September 2011
Unsecured credit facility of €500 million is for a minumum term of 5 years and a maximum term of 7 years.
22 September 2011
DSM repurchased 404,055 shares from 15 to 21 September 2011 at an average price of €32.52.
16 September 2011
On 13 September 2011 a fatal accident took place on DSM property in Augusta (Georgia, USA), in which one contractor lost his life. DSM deeply regrets this tragic accident and expresses its sympathy to the victim’s family.
15 September 2011
DSM repurchased 641,065 shares from 7 to 14 September 2011 at an average price of €31.84.
13 September 2011
DSM Personalized Nutrition’s corporate wellness business will become part of Viocare’s operations.
8 September 2011
DSM once again retained its number one position in the chemical industry sector in the Dow Jones Sustainability World Index.
7 September 2011
DSM intends to repurchase 4,000,000 ordinary shares to cover commitments under management and personnel option plans.
31 August 2011
Sinochem Group has taken a 50% equity interest in DSM Anti-Infectives for total cash consideration of €210 million on a cash and debt-free basis with 1 January 2011 as effective date.
24 August 2011
Exchange ratio for the dividend in shares has been determined at 1 new ordinary share for every 72.338 existing ordinary shares.
23 August 2011
Philip Eykerman will join DSM as Executive Vice President Corporate Strategy & Acquisitions.
2 August 2011
Q2 EBITDA from continuing operations €339 million, above both Q2 2010 and Q1 2011.
27 July 2011
DSM and Nutreco confirm they have decided to jointly explore the possibility to acquire Provimi.
12 July 2011
DSM acquires interest in manufacturer of environmentally friendly UV-curable resins.
4 July 2011
Ventures cover marketing and production of engineering plastics compounds in Russia.
4 July 2011
Acquisition of Vitatene allows DSM to strengthen the natural carotenoids offerings of its nutrition business as consumer demand for natural products continues to grow.
28 June 2011
Acquisition adds new yeast and enzyme technologies for second generation biofuels.
24 May 2011
Exchange ratio for the dividend in shares has been determined at 1 new ordinary share for every 48.077 existing ordinary shares.
17 May 2011
DSM repurchased 264,319 shares from 13 to 16 May 2011 at an average price of €46.56 and concluded the program to repurchase 5,000,000 shares.
13 May 2011
DSM repurchased 502,059 shares from 6 to 12 May 2011 at an average price of €46.05.
10 May 2011
Acquisition allows DSM to strengthen the natural carotenoids offerings of its nutrition business as consumer demand for natural products continues to grow.
9 May 2011
Feike Sijbesma received award in recognition of his outstanding contribution to development and innovation in industrial biotechnology.
9 May 2011
New chemical building block offers bio-based alternative.
6 May 2011
DSM repurchased 601,953 shares from 29 April to 5 May 2011 at an average price of €45.78.
3 May 2011
DSM completes sale of DSM Elastomers to LANXESS for €310 million on a cash and debt-free basis.
29 April 2011
DSM repurchased 435,987 shares from 26 to 28 April 2011 at an average price of €45.33.
28 April 2011
DSM declares dividend for 2010 of €1.35 per ordinary share of €1.50 par value.
28 April 2011
DSM held its Annual General Meeting of Shareholders on 28 April 2011. Shareholders approved all resolutions on the agenda.
28 April 2011
Summary of the resolutions at DSM's Annual General Meeting of Shareholders 2011.
27 April 2011
Q1 EBITDA from continuing operations up 14% to €325 million.
26 April 2011
DSM intends to appoint Mr. Atzo Nicolaï (1960), currently Member of the Dutch House of Representatives (“Tweede Kamer der Staten-Generaal”) with effect from 1 June 2011.
26 April 2011
DSM repurchased 368,294 shares from 15 to 21 April 2011 at an average price of €42.70.
15 April 2011
DSM repurchased 326,090 shares from 8 to 14 April 2011 at an average price of €43.53.
8 April 2011
DSM repurchased 376,582 shares from 1 to 7 April 2011 at an average price of €43.97.
8 April 2011
DSM will implement changes in the presentation of its financial results as from Q1 2011.
1 April 2011
DSM repurchased 349,822 of its own shares from 25 to 31 March 2011 at an average price of €43.34.
25 March 2011
DSM repurchased 331,532 shares from 18 to 24 March 2011 at an average price of €42.33.
18 March 2011
DSM repurchased 479,895 shares from 11 to 17 March 2011 at an average price of €41.13.
11 March 2011
DSM repurchased 499,687 shares from 4 to 10 March at an average price of € 43.49.
4 March 2011
DSM repurchased 463,780 shares from 24 February to 3 March 2011 at an average price of €42.74.
1 March 2011
Partnership with Kemrock Industries in India for the production of specialty composite resins in India.
28 February 2011
Acquisition adds new growth platform for healthy and natural food ingredients, focused on Omega-3 DHA and Omega-6 ARA.
25 February 2011
DSM successfully completes subsequent offering period to its all-cash tender offer.
25 February 2011
Jinling DSM Resins Co., Ltd. (JDR) will invest approximately €50 million in a new production facility for composite resins in Nanjing, China.
25 February 2011
Supervisory Board proposes appointing Mr. Stefan Doboczky to DSM's Managing Board with effect from 1 May 2011.
23 February 2011
Full-year operating profit continuing operations up 74% to €752 million, dividend increase of 12.5% per ordinary share proposed.
23 February 2011
Royal DSM N.V today introduces a new company brand: Bright Science. Brighter Living™. The new brand is symbolic of the transition to the ‘new’ DSM.
23 February 2011
DSM intends to repurchase 5,000,000 ordinary shares to cover commitments under management and personnel option plans.
22 February 2011
DSM Supervisory Board has appointed Rob Routs as its new Chairman.
21 February 2011
Tender offer to purchase all outstanding shares of common stock of Martek Biosciences Corporation successful.
17 February 2011
Counsel of the National Competition Commission approves acquisition.
17 February 2011
DSM to acquire the majority shareholding in Shandong ICD High Performance Fibre Co Ltd. based in Laiwu, China.
16 February 2011
DSM will use new P&L from the publication of the full year 2010 results onwards.
1 February 2011
Waiting period for DSM's offer for all outstanding shares of Martek Biosciences Corporation at a price of $31.50 per share closes.
28 January 2011
DSM and United States Agency for International Development (USAID) to collaborate and collectively work to meet the nutritional challenges presented in the developing world.
20 January 2011
DSM Engineering Plastics to enter two joint ventures with KA.
13 January 2011
DSM commences tender offer for all outstanding shares of common stock of Martek Biosciences Corporation at a price of $31.50 per share.
12 January 2011
DSM holds a 4.95% stake in Danisco which has been acquired some years ago.
Leia os comunicados de imprensa dos últimos três anos da Firmenich.
19 June 2026
8 April 2025
9 May 2023
2 May 2023
20 March 2023
6 February 2023
31 January 2023
13 December 2022
11 October 2022
5 August 2022
12 July 2022
30 May 2022
23 March 2022
10 February 2022
7 December 2021
1 December 2021
15 November 2021
5 November 2021
7 October 2021
6 October 2021
27 September 2021
6 August 2021
30 June 2021
17 June 2021
8 March 2021
11 February 2021
9 February 2021
4 February 2021
8 December 2020
Read more about news from dsm-firmenich and its businesses
Sustainability is fundamental to how dsm-firmenich brings progress to life – for people and planet.
Through science and innovation, we are creating a world of potential for investors.